Literature DB >> 27879559

Angiotensin II in Refractory Septic Shock.

Elio Antonucci1, Patrick J Gleeson, Filippo Annoni, Sara Agosta, Sergio Orlando, Fabio Silvio Taccone, Dimitrios Velissaris, Sabino Scolletta.   

Abstract

Refractory septic shock is defined as persistently low mean arterial blood pressure despite volume resuscitation and titrated vasopressors/inotropes in patients with a proven or suspected infection and concomitant organ dysfunction. Its management typically requires high doses of catecholamines, which can induce significant adverse effects such as ischemia and arrhythmias. Angiotensin II (Ang II), a key product of the renin-angiotensin-aldosterone system, is a vasopressor agent that could be used in conjunction with other vasopressors to stabilize critically ill patients during refractory septic shock, and reduce catecholamine requirements. However, very few clinical data are available to support Ang II administration in this setting. Here, we review the current literature on this topic to better understand the role of Ang II administration during refractory septic shock, differentiating experimental from clinical studies. We also consider the potential role of exogenous Ang II administration in specific organ dysfunction and possible pitfalls with Ang II in sepsis. Various issues remain unresolved and future studies should investigate important topics such as: the optimal dose and timing of Ang II administration, a comparison between Ang II and the other vasopressors (epinephrine; vasopressin), and Ang II effects on microcirculation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27879559     DOI: 10.1097/SHK.0000000000000807

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  13 in total

1.  Angiotensin II.

Authors:  Danial E Baker; Terri L Levien
Journal:  Hosp Pharm       Date:  2018-05-24

Review 2.  The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature.

Authors:  Laurence W Busse; Michael T McCurdy; Osman Ali; Anna Hall; Huaizhen Chen; Marlies Ostermann
Journal:  Crit Care       Date:  2017-12-28       Impact factor: 9.097

3.  Angiotensin II in vasodilatory shock: lights and shadows.

Authors:  Elio Antonucci; Sara Agosta; Yasser Sakr
Journal:  Crit Care       Date:  2017-11-14       Impact factor: 9.097

4.  Angiotensin II Use in Refractory Multisystem Shock: A Case Report.

Authors:  Mohamed Ahmed; Saba Habis; Ahmed Mahmoud; Cedric Rutland; Rasha Saeed
Journal:  Cureus       Date:  2018-11-30

Review 5.  Outcome of acute kidney injury: how to make a difference?

Authors:  Matthieu Jamme; Matthieu Legrand; Guillaume Geri
Journal:  Ann Intensive Care       Date:  2021-04-15       Impact factor: 6.925

6.  Effectiveness of Angiotensin II for Catecholamine Refractory Septic or Distributive Shock on Mortality: A Propensity Score Weighted Analysis of Real-World Experience in the Medical ICU.

Authors:  Michele Quan; Nam Cho; Thomas Bushell; Joseph Mak; Nolan Nguyen; Jane Litwak; Nicholas Rockwood; H Bryant Nguyen
Journal:  Crit Care Explor       Date:  2022-01-18

Review 7.  COVID-19 and the cardiovascular system: an update.

Authors:  Joshua K Salabei; Zekarias T Asnake; Zeeshan H Ismail; Kipson Charles; Gregory-Thomas Stanger; Abdullahi H Abdullahi; Andrew T Abraham; Peters Okonoboh
Journal:  Am J Med Sci       Date:  2022-02-11       Impact factor: 3.462

Review 8.  Promotion of vascular integrity in sepsis through modulation of bioactive adrenomedullin and dipeptidyl peptidase 3.

Authors:  D van Lier; M Kox; P Pickkers
Journal:  J Intern Med       Date:  2020-12-30       Impact factor: 8.989

Review 9.  Angiotensin II: a new therapeutic option for vasodilatory shock.

Authors:  Rachel L Bussard; Laurence W Busse
Journal:  Ther Clin Risk Manag       Date:  2018-07-26       Impact factor: 2.423

10.  Haemodynamic monitoring of COVID-19 patients: Classical methods and new paradigms.

Authors:  Karim Bendjelid; Laurent Muller
Journal:  Anaesth Crit Care Pain Med       Date:  2020-09-04       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.